Status:
COMPLETED
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Coronary Arteriosclerosis
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose b...
Eligibility Criteria
Inclusion
- High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
- Triglycerides up to 600 mg/dL.
- History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events.
Exclusion
- Pregnancy or lactation, use of high statin doses (\>40mg) at baseline, liver or renal problems
- Use of other drugs that would interfere with evaluation of efficacy or cause safety problems
- Uncontrolled hypertension, diabetes or hypothyroidism
- Recent cardiac event of procedure
- High baseline CPK levels
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2004
Estimated Enrollment :
595 Patients enrolled
Trial Details
Trial ID
NCT00442325
Start Date
January 1 2003
End Date
February 1 2004
Last Update
February 18 2021
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ioannina, Greece
2
Pfizer Investigational Site
Kallithea, Athens, Greece
3
Pfizer Investigational Site
Pireaus, Greece
4
Pfizer Investigational Site
Thessaloniki, Greece